384 related articles for article (PubMed ID: 26181187)
1. Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the Patient.
Basch E; Geoghegan C; Coons SJ; Gnanasakthy A; Slagle AF; Papadopoulos EJ; Kluetz PG
JAMA Oncol; 2015 Jun; 1(3):375-9. PubMed ID: 26181187
[TBL] [Abstract][Full Text] [Related]
2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes supporting anticancer product approvals.
Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
[TBL] [Abstract][Full Text] [Related]
4. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
5. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.
; ;
Health Qual Life Outcomes; 2006 Oct; 4():79. PubMed ID: 17034633
[TBL] [Abstract][Full Text] [Related]
6. Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada.
Kluetz PG; O'Connor DJ; Soltys K
Lancet Oncol; 2018 May; 19(5):e267-e274. PubMed ID: 29726391
[TBL] [Abstract][Full Text] [Related]
7. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M;
Value Health; 2003; 6(5):522-31. PubMed ID: 14627058
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
[TBL] [Abstract][Full Text] [Related]
9. US FDA patient-reported outcome guidance: great expectations and unintended consequences.
Fehnel S; DeMuro C; McLeod L; Coon C; Gnanasakthy A
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):441-6. PubMed ID: 23977972
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
Bottomley A; Jones D; Claassens L
Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
[TBL] [Abstract][Full Text] [Related]
11. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
12. Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology.
Rowe-Rendleman CL
Pharm Res; 2019 Feb; 36(4):54. PubMed ID: 30790065
[TBL] [Abstract][Full Text] [Related]
13. Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.
Gondek K; Sagnier PP; Gilchrist K; Woolley JM
J Clin Oncol; 2007 Nov; 25(32):5087-93. PubMed ID: 17991926
[TBL] [Abstract][Full Text] [Related]
14. Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.
Kluetz PG; Kanapuru B; Lemery S; Johnson LL; Fiero MH; Arscott K; Barbachano Y; Basch E; Campbell M; Cappelleri JC; Cella D; Cleeland C; Coens C; Daniels S; Denlinger CS; Fairclough DL; Hillard JR; Minasian L; Mitchell SA; O'Connor D; Patel S; Rubin EH; Ryden A; Soltys K; Sridhara R; Thanarajasingam G; Velikova G; Coons SJ
Value Health; 2018 Jun; 21(6):742-747. PubMed ID: 29909880
[TBL] [Abstract][Full Text] [Related]
15. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
16. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
17. The FDA and the person with cancer: give PROs a chance.
Cella D
Oncology (Williston Park); 2006 Apr; 20(4):436. PubMed ID: 16683418
[No Abstract] [Full Text] [Related]
18. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010.
DeMuro C; Clark M; Mordin M; Fehnel S; Copley-Merriman C; Gnanasakthy A
Value Health; 2012 May; 15(3):443-8. PubMed ID: 22583454
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges.
Hao Y
Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):407-20. PubMed ID: 20715918
[TBL] [Abstract][Full Text] [Related]
20. FDA review divisions: performance levels and the impact on drug sponsors.
Milne CP; Kaitin KI
Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
